Skip to content
10-Q

Quarterly Report

ORAMED PHARMACEUTICALS INC. ORMP

0001213900-26-059112

← back to feed
Filed
May 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 19, 2026 40.93M sh
Shares Diluted Q1 2026 · Mar 31, 2026 41.97M sh
Shares Diluted Q1 2026 · Mar 31, 2025 41.23M sh
Dividends Paid Q1 2026 · Mar 31, 2026 $10.36M
Capex Q1 2026 · Mar 31, 2026 $5K
Capex Q1 2026 · Mar 31, 2025 $3K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.92M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.52M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $13.2M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $45.95M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.56M
Current Liabilities Q1 2026 · Dec 31, 2025 $19.09M
Current Assets Q1 2026 · Mar 31, 2026 $68.15M
Current Assets Q1 2026 · Dec 31, 2025 $133.27M
Total Assets Q1 2026 · Mar 31, 2026 $268.85M
Total Assets Q1 2026 · Dec 31, 2025 $230.86M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.91
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.19
Eps Basic Q1 2026 · Mar 31, 2026 $0.94
Eps Basic Q1 2026 · Mar 31, 2025 −$0.19
Sga Expense Q1 2026 · Mar 31, 2026 $2.07M
Sga Expense Q1 2026 · Mar 31, 2025 $2.31M
Rd Expense Q1 2026 · Mar 31, 2026 $1.59M
Rd Expense Q1 2026 · Mar 31, 2025 $2.21M
Net Income Q1 2026 · Mar 31, 2026 $38.31M
Net Income Q1 2026 · Mar 31, 2025 −$7.64M
Operating Income Q1 2026 · Mar 31, 2026 −$3.66M
Operating Income Q1 2026 · Mar 31, 2025 −$4.5M
Gross Profit Q1 2026 · Mar 31, 2025 $13K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $1.99M
Revenue Q1 2026 · Mar 31, 2025 $2M